3BIY image
Deposition Date 2007-12-02
Release Date 2008-02-12
Last Version Date 2024-02-21
Entry Detail
PDB ID:
3BIY
Keywords:
Title:
Crystal structure of p300 histone acetyltransferase domain in complex with a bisubstrate inhibitor, Lys-CoA
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.70 Å
R-Value Free:
0.21
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 43
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Histone acetyltransferase p300
Gene (Uniprot):EP300
Mutations:K1637R, M1652G
Chain IDs:A
Chain Length:380
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
The structural basis of protein acetylation by the p300/CBP transcriptional coactivator
Nature 451 846 850 (2008)
PMID: 18273021 DOI: 10.1038/nature06546

Abstact

The transcriptional coactivator p300/CBP (CREBBP) is a histone acetyltransferase (HAT) that regulates gene expression by acetylating histones and other transcription factors. Dysregulation of p300/CBP HAT activity contributes to various diseases including cancer. Sequence alignments, enzymology experiments and inhibitor studies on p300/CBP have led to contradictory results about its catalytic mechanism and its structural relation to the Gcn5/PCAF and MYST HATs. Here we describe a high-resolution X-ray crystal structure of a semi-synthetic heterodimeric p300 HAT domain in complex with a bi-substrate inhibitor, Lys-CoA. This structure shows that p300/CBP is a distant cousin of other structurally characterized HATs, but reveals several novel features that explain the broad substrate specificity and preference for nearby basic residues. Based on this structure and accompanying biochemical data, we propose that p300/CBP uses an unusual 'hit-and-run' (Theorell-Chance) catalytic mechanism that is distinct from other characterized HATs. Several disease-associated mutations can also be readily accounted for by the p300 HAT structure. These studies pave the way for new epigenetic therapies involving modulation of p300/CBP HAT activity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures